Glenmark launches Remogliflozin combo in India; GeneCentric Therapeutics buys Select ImmunoGenomics
→ India’s Glenmark in April launched domestically a new SGLT2 inhibitor called Remogliflozin — marking the first-ever launch of the diabetes drug, which was partly …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
